SCHEMBL6288397

SCHEMBL6288397

COc1ccc(-c2nc(Nc3cc(OC)c(OC)c(OC)c3)c3c(C)nc(C4CCCC4)n3n2)cc1S(=O)(=O)N1CCOCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.47
BRD2 P25440 1/20 0.47
BRD3 Q15059 1/20 0.47
KDM4E B2RXH2 2/20 0.47
MAPT P10636 2/20 0.47
KMT2A Q03164 3/20 0.43
SYK P43405 3/20 0.41
ALDH1A1 P00352 6/20 0.41
MAPK1 P28482 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GAA P10253 1/20 0.41
PI4KB Q9UBF8 2/20 0.40
PI4KA P42356 1/20 0.40
LMNA P02545 4/20 0.40
MEN1 O00255 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
USP2 O75604 1/20 0.40
HSD17B10 Q99714 1/20 0.40
RAB9A P51151 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6288393 0.85 ALDH1A1 (0.42) KDM4EMAPTKMT2AALDH1A1MAPK1
SCHEMBL6291858 0.81 MEN1 (0.40) KDM4EMAPTKMT2ASYKALDH1A1
SCHEMBL6288422 0.80 BRD4 (0.47) BRD4BRD2BRD3KMT2ASYK
SCHEMBL6286872 0.79 BRD4 (0.43) BRD4BRD2BRD3KMT2ASYK
SCHEMBL6291400 0.79 ALDH1A1 (0.41) KDM4EMAPTKMT2ASYKALDH1A1
SCHEMBL6288417 0.79 PDE5A (0.55) BRD4BRD2BRD3KMT2ASYK
SCHEMBL6288424 0.79 ABCG2 (0.45) KDM4EKMT2AALDH1A1MAPK1LMNA
SCHEMBL6291395 0.75 BCL6 (0.42) KDM4EMAPTKMT2AALDH1A1MAPK1
SCHEMBL6288564 0.75 ABCG2 (0.43) KDM4EMAPTKMT2AALDH1A1MAPK1
SCHEMBL6291864 0.73 BRD4 (0.42) BRD4BRD2BRD3KMT2ASYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936609-B2 Imidazotriazines for use as phosphodiesterase inhibitors BAYER HEALTHCARE AG (DE) 2005-08-30 US disclosed
US-20040249148-A1 Imidazotriazines for use as phosphodiesterase inhibitors BAYER HEALTHCARE AG (DE) 2004-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040249148-A1 Imidazotriazines for use as phosphodiesterase inhibitors PDE3A, PDE2A, PDE4A BRD4 1636/4885BRD2 2054/4885BRD3 1904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.